Patient Education, Trial Design, Post-Market Surveillance, and Adoption Barriers

Dr. Soares frames patient education conversations around reassurance and clarity. The core message for patients familiar with a reference radioligand therapy is that the RLE is designed to perform comparably in terms of efficacy and safety. Any differences that do exist are most likely operational, related to institutional logistics rather than clinical experience. The term generic should be explicitly avoided, as it introduces inaccurate expectations about product identity. Scientifically accurate but accessible language, focusing on what matters to the patient, is the goal of informed consent discussions.

Dr. Hendifar adds that for approved therapies outside clinical trials, the approval pathway itself rarely needs to enter patient conversations in detail. The clinical discussion centers on what the patient will experience, such as treatment schedule, expected effects, potential toxicities, and not regulatory pathway specifics. The RLE term helps the clinical team speak accurately to each other, which then supports clearer patient communication downstream.

Dr. El-Haddad addresses future trial design implications, framing the availability of RLEs as an accelerant of innovation. The 505(b)(2) pathway allows development of new indications and combination strategies without complete duplication of existing data packages, making clinical programs faster and more efficient. Post-market surveillance and real-world data collection will be important for both RLEs and reference products to capture long-term safety signals, including bone marrow and renal toxicities, that are impractical to characterize fully in pivotal trials.

Dr. Soares identifies the key adoption barrier as unfamiliarity: clinicians are comfortable with brand name, generic, and biosimilar categories, and RLEs don't fit neatly into any of them. Additional practical barriers include formulary review processes, payer questions, staff education requirements, and institution-specific procedural differences for handling. The most effective adoption strategy combines education, multidisciplinary communication, and early institutional real-world experience. Early adopters who share their operational experiences will be critical to accelerating broader acceptance across the nuclear medicine community.